Infectious Diarrhea: An Overview

Current Gastroenterology Reports

Volumn 16, Issue 8, 2014, Pages

  Dickinson, Brandon ^a   Surawicz, Christina M ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Clostridium difficile infection (CDI); Fecal microbiota transplant (FMT); Infectious diarrhea; Oral rehydration solution (ORS); Post infectious irritable bowel syndrome (PI IBS); Probiotics; Recurrent Clostridium difficile infection (RCDI); Zinc

Indexed keywords

EID: 84904518744     PISSN: 15228037     EISSN: 1534312X     Source Type: Journal    
DOI: 10.1007/s11894-014-0399-8     Document Type: Review

References (70)

1. World Health Organization: Diarrhoeal disease. Available at http://www.who.int/mediacentre/factsheets/fs330/en/. Accesses April 4, 2014.
2. Centers for Disease Control and Prevention (CDC). Incidence and trends of infection with pathogens transmitted commonly through food—foodborne diseases active surveillance network, 10 U.S. sites, 1996–2012. MMWR Morb Mortal Wkly Rep. 2013;62(15):283–7.
3. Gould LH, Demma L, Jones TF, et al. Hemolytic uremic syndrome and death in persons with Escherichia coli 0157:H7 infection, foodborne disease active surveillance network sites, 2000–2006. Clin Infect Dis. 2009;49:1480–5.
4. Frank C, Werber D, Cramer JP, et al. Epidemic profile of Shiga-toxin-producing Escherichia coli O104:H4 outbreak in Germany. N Eng J Med. 2011;365(19):1771–80.
5. Mellmann A, Harmsen D, Cummings CA, et al. Prospective genomic characterization of the German enterohemorrhagic Escherichia coli O104:H4 outbreak by rapid next generation sequencing technology. PLoS ONE. 2011;6:e22751.
6. Rhode H, Qin J, Cui Y, et al. Open-source genomic analysis of Shiga-toxin-producing E. coli O104:H4. N Eng J Med. 2011;365:718–24.
7. Barton Behravesh C, Jones TF, Vugia DJ, et al. Deaths associated with bacterial pathogens transmitted commonly through food: foodborne disease active surveillance network (FoodNet), 1996–2005. J Infect Dis. 2011;204:263–7.
8. McCollum JT, Cronquist AB, Silk BJ, et al. Multistate outbreak of listeriosis associated with cantaloupe. N Eng J Med. 2013;369(10):944–53.
9. Arvelo W, Hinkle CJ, Nguyen TA, et al. Transmission risk factors and treatment of pediatric shigellosis during a large daycare center-associated outbreak of multidrug resistant Shigella sonnei: implications for the management of shigellosis outbreaks among children. Pediatr Infect Dis J. 2009;28:976–80.
10. CDC. Notes from the field: outbreak of infections caused by Shigella sonnei with decreased susceptibility to azithromycin—Los Angeles, California, 2012. MMWR Morb Mortal Wkly Rep. 2013;62(9):171.
11. McFarland LV. Emerging therapies for Clostridium difficile infections. Exp Opin Emerg Drugs. 2011;16:425–39.
12. O’brien JA, Lahue BJ, Caro JJ, et al. The emerging infectious challenge of Clostridium difficile-associated disease in Massachusetts hospitals: clinical and economic consequences. Infect Control Hosp Epidemiol. 2007;28:1219–27.
13. O’Connor JR, Johnson S, Gerding D. Clostridium difficile infection caused by the epidemic BI/NAP1/027 strain. Gastroenterology. 2009;136(6):1913–24.
14. Pepin J, Saheb N, Coulombe MA, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile—associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis. 2005;41(9):1254–60.
15. Gupta A, Khanna S. Community-acquired Clostridium difficile infection: an increasing public health threat. Infect Drug Resist. 2014;7:63–72.
16. Otten AM, Reid-Smith RJ, Fazil A, Weese JS. Disease transmission model for community-associated Clostridium difficile infection. Epidemiol Infect. 2010;138(6):901–14.
17. Bavishi C, Dupont HL. Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infection. Aliment Pharmacol Ther. 2011;34(11–12):1269–81.
18. Ozaki E, Kato H, Kita H, et al. Clostridium difficile colonization in healthy adults: transient colonization and correlation with enterococcal colonization. J Med Microbiol. 2004;53(2):167–72.
19. Khanna S, Keddis M, Noheria A, et al. The epidemiology of Clostridium difficile infection in children: a population based study. Clin Infect Dis. 2013;56(10):1401–6.
20. Chitnis A, Holzbauer S, Belflower R, et al. Epidemiology of community-associated Clostridium difficile infection, 2009–2011. JAMA Intern Med. 2013;173:1359–67.
21. Khanna S, Pardi DS, Aronson SL, et al. The epidemiology of community-acquired Clostridium difficile infection: a population-based study. Am J Gastroenterol. 2012;107(1):89–95.
22. Janarthanan S, Ditah I, Adler DG, et al. Clostridium difficile associated diarrhea and proton pump inhibitor therapy—a meta-analysis. Am J Gastroenterol. 2012;107:1001–10.
23. Kwok CS, Arthur AK, Anibueze CI, et al. Risk of Clostridium difficile infection with acid suppression agents and antibiotics: meta-analysis. Am J Gastroenterol. 2012;107:1011–9.
24. Barletta JF, El-Ibiary SY, Davis LE, et al. Proton pump inhibitors and the risk for hospital-acquired Clostridium difficile infection. Mayo Clin Proc. 2013;88(10):1085–90.
25. Buendgens L, Bruensing J, Matthes M, et al.: Administration of proton pump inhibitors in critically ill medical patients is associated with increased risk of developing Clostridium difficile-associated diarrhea. J Crit Care 2014, S0883-9441(14)00079-3. doi: 10.1016/j.jcrc.2014.03.002
26. Drug Safety Communication - FDA Clostridium difficile-associated diarrhea (CDAD) can be associated with stomach acid drugs. http://www.fda.gov/Safety/MedWatch?SafetyInformation?Safety AlertsforHumanMedicalProducts/ucm290838.htm (assessed 2 April 2014).
27. Freedberg DE, Salmasian H, Friedman C, Abrams JA. Proton pump inhibitors and risk for recurrent Clostridium difficile infection among inpatients. Am J Gastroenterol. 2013;108(11):1794–801.
28. Khanna S, Aronson S, Kammer P, et al. Gastric acid suppression and outcomes in Clostridium difficile infection: a population based study. Mayo Clin Proc. 2012;87(7):636–42.
29. Surawicz CM, Brandt LJ, Binion DG, et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol. 2013;108(4):478–9. New guidelines for the diagnosis and treatment of Clostridium difficile infections. A great resource for a comprehensive review of the subject.
30. Kelly C, Lamont J. Clostridium difficile—more difficult than ever. N Engl J Med. 2008;359:1932–40.
31. Louie TJ, Miller MA, Mullane KM, et al. Fidaxomicin versus vancomycin for Clostridium difficile-associated disease in Quebec, Canada. Clin Infect Dis. 2006;42:758–64.
32. Taur Y, Pamer EG. Harnessing microbiota to kill a pathogen: fixing the microbiota to treat Clostridium difficile infections. Nat Med. 2014;20(3):246–7. An interesting article from Nature that highlights the need for greater understanding of the mechanism by which FMT is effective for recurrent CDI in order to potentially achieve the same effect as FMT but with greater ease of administration.
33. Tvede M, Rask-Madsen J. Bacteriotherapy for chronic relapsing Clostridium difficile diarrhoea in six patients. Lancet. 1989;1(8648):1156–60.
34. Hamilton M, Weingarden A, Sadowsky M, Khoruts A. Standardized frozen preparation for transplantation of fecal microbiota for recurrent Clostridium difficile infection. Am J Gastroenterol. 2012;107(5):761–7.
35. Matilla E, Uusitalo-Seppala R, Wuorela M, et al. Fecal transplantation, through colonoscopy, is effective therapy for recurrent Clostridium difficile infection. Gastroenterology. 2012;142:490–6.
36. Gough E, Shaikh H, Manges A. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infect Dis. 2011;53:994–1002.
37. Van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Eng J Med. 2013;368(5):407–15. First randomized controlled trial using fecal microbiota transplantation for the treatment of recurrent Clostridium difficile infection.
38. Khoruts A, Dicksved J, Jansson JK, et al. Changes in the composition of the human fecal microbiome after bacteriotherapy for recurrent Clostridium difficile-associated diarrhea. J Clin Gastroenterol. 2010;44(5):354–60.
39. Sorg JA, Sonenshein AL. Bile salts and glycine as cogerminants for Clostridium difficile spores. J Bacteriol. 2008;190(7):2505–12.
40. Sorg JA, Sonenshein AL. Inhibiting the initiation of Clostridium difficile spore germination using analogs of chenodeoxycholic acid, a bile acid. J Bacteriol. 2012;192(19):4983–90.
41. Smith PM, Howitt MR, Panikov N, et al. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science. 2013;341(6145):569–73.
42. Ley RE. Harnessing microbiota to kill a pathogen: the sweet tooth of Clostridium difficile. Nat Med. 2014;20(3):248–9.
43. Ng KM, Ferreyra JA, Higginbottom SK, et al. Microbiota-liberated host sugars facilitate post-antibiotic expansion of enteric pathogens. Nature. 2013;502(7469):96–9.
44. Binder HJ, Brown I, Ramakrishna BS, Young GP. Oral rehydration therapy in the second decade of the twenty-first century. Curr Gastroenterol Rep. 2014;16(3):376. An excellent review on the history of oral rehydration therapy, including improvements that have been made in the solution over time and current research efforts to further improve its efficacy and delivery.
45. Desjeux JF, Briend A, Butzner JD. Oral rehydration solution in the year 2000: pathophysiology, efficacy and effectiveness. Baillieres Clin Gastroenterol. 1997;11:509–27.
46. Lin R, Murtazina R, Cha B, et al. D-glucose acts via sodium/glucose cotransporter 1 to increase NHE3 in mouse jejunal brush border by a Na+/H + exchange regulatory factor 2-dependent process. Gastroenterology. 2011;140:560–71.
47. Duggan C, Fontaine O, Pierce NF, et al. Scientific rationale for a change in the composition of oral rehydration solution. JAMA. 2004;291:2628–31.
48. Ramakrishna BS, Venkataraman S, Srinivasan P, et al. Amylase-resistant starch plus oral rehydration solution for cholera. N Engl J Med. 2000;342:308–13.
49. Raghupathy P, Ramakrishna BS, Oommen SP, et al. Amylase-resistant starch as adjunct to oral rehydration therapy in children with diarrhea. J Pediatr Gastr Nutr. 2006;42:362–8.
50. Balakrishnan BS, Venkataraman S, Mohen V, et al. Amylase resistant starch in hypo-osmolar oral rehydration solution for the treatment of acute severe watery diarrhea in adults. PLoS ONE. 2008;3:e1587.
51. Subramanya S, Balakrishnan BS, Ramakrishna S, et al. Evaluation of oral rehydration solution by whole gut perfusion in rats: effects of osmolarity, sodium concentration and resistant starch. J Pediatr Gastroenterol Nutr. 2006;43:568–77.
52. Penny ME. Zinc supplementation in public health. Ann Nutr Metab. 2013;62(1):31–42.
53. WHO/UNICEF joint statement: clinical management of acute diarrhoea. The United Nations Children's Fund/World Health Organization, 2004. http://whqlibdoc.who.int.offcampus.lib.washington.edu/hq/2004/WHO_FCH_CAH_04.7.pdf (accessed April 3, 2014).
54. Lazzerini M, Ronfani L. Oral zinc for treating diarrhoea in children. Cochrane Database Syst Rev. 2013;1, CD005436.
55. Fasano A. Toxin and the gut: role in human disease. Gut. 2002;50:9–14.
56. Surawicz CM. Mechanisms of Diarrhea. Curr Gastroenterol Rep. 2010;12(4):236–41.
57. Berni Canani R, Cirillo P, Buccigrossi V, et al. Zinc inhibits cholera toxin-induced, but not Escherichia coli heat-stable enterotoxin-induced, ion secretion in human enterocytes. J Infect Dis. 2006;191:1072–7.
58. BerniCanani R, Secondo A, Passariello A, et al. Zinc inhibits calcium-mediated and nitric oxide-mediated ion secretion in human enterocytes. Eur J Pharmacol. 2010;626:266–70.
59. Berni Canani R, Buccigrossi V, Passariello A. Mechanisms of action of zinc in acute diarrhea. Curr Opin Gastroenterol. 2011;27:8–12.
60. Salgueiro MJ, Zubillaga M, Lysionek A, et al. Zinc status and immune system relationship: a review. Biol Trace Elem Res. 2000;76:193–205.
61. McFarland LV. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am J Gastroenterol. 2006;101:812–22.
62. Johnston BC, Ma SS, Goldenberg JZ, et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea: a systematic review and meta-analysis. Ann Intern Med. 2012;157(12):878–88. Recent Cochrane review looking at the use of probiotics in the prevention of Clostridium difficile infection.
63. Allen SJ, Wareham K, Wang D, et al. Lactobacilli and bifidobacteria in the prevention of antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in older patients (PLACIDE): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2013;382(9900):1249–57.
64. Spiller R, Garsed K. Postinfectious irritable bowel syndrome. Gastroenterology. 2009;136:1979–88.
65. Stewart GT. Post-dysenteric colitis. Br Med J. 1950;1:405–9.
66. Ghoshal UC, Ranjan P. Post-infectious irritable bowel syndrome: the past, the present, the future. J Gastroenterol Hepatol. 2011;26(3):94–101.
67. Gorbach SL, Neale G, Levitan R, et al. Alterations in human intestinal microflora during experimental diarrhoea. Gut. 1970;11:1–6.
68. Krogius-Kurikka L, Lyra A, Malinen E, et al. Microbial community analysis reveals high level phylogenetic alterations in the overall gastrointestinal microbiota of diarrhoea-predominant irritable bowel syndrome sufferers. BMC Gastroenterol. 2009;9:95.
69. Gwee KA, Collins SM, Read NW, et al. Increased rectal mucosal expression of interleukin 1beta in recently acquired post-infectious irritable bowel syndrome. Gut. 2003;52:523–6.
70. Pimentel M, Chatterjee S, Chang C, et al. A new rat model links two contemporary theories in irritable bowel syndrome. Dig Dis Sci. 2008;53(4):982–9.